Clinical Application and Research Progress of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma--Review.
10.19746/j.cnki.issn.1009-2137.2022.06.046
- Author:
Hai-Ying ZHANG
1
;
Yan-Li YANG
2
Author Information
1. Department of Pathology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China.
2. Department of Pathology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, Gansu Province, China. E-mail: a06974723@163.com.
- Publication Type:Journal Article
- Keywords:
liquid biopsy;
circulating tumor DNA;
diffuse large B-cell lymphoma
- MeSH:
Humans;
Circulating Tumor DNA;
Lymphoma, Large B-Cell, Diffuse
- From:
Journal of Experimental Hematology
2022;30(6):1917-1921
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, its diagnosis and prognosis evaluation mainly depends on tissue biopsy and imaging examination. As a part of liquid biopsy, circulating tumor DNA (ctDNA) is a novel noninvasive and real-time tumor-specific biomarker, which can reliably reflect the comprehensive tumor genetic profiles, and it plays an important role in assisting early diagnosis, monitoring the curative effect, prognosis evaluation and prediction of recurrence of DLBCL. This review summarized recent research progress of ctDNA in DLBCL.
